Mercado da Doença Celíaca da América do Norte e Europa – Tendências da Indústria e Previsão para 2031

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Mercado da Doença Celíaca da América do Norte e Europa – Tendências da Indústria e Previsão para 2031

  • Pharmaceutical
  • Publish Reports
  • Dec 2023
  • Country Level
  • 350 Páginas
  • Número de tabelas: 380
  • Número de figuras: 95

North America And Europe Celiac Disease Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Diagram Período de previsão
2024 –2031
Diagram Tamanho do mercado (ano base )
USD 94,325.34 Thousand
Diagram Tamanho do mercado ( Ano de previsão)
USD 193,364.33 Thousand
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Manequim1
  • Manequim2
  • Manequim3
  • Manequim4
  • Manequim5

Mercado da doença celíaca da América do Norte e da Europa, por tipo de tratamento (corticosteróides, imunossupressores e outros), tipo de doença (doença celíaca clássica, doença celíaca não clássica, doença celíaca refractária, doença celíaca potencial e dermatite herpetiforme), tipo de medicamento (genéricos e de marca ), Tipo de prescrição (prescrição e venda livre), forma farmacêutica (comprimido, cápsulas, injeção e outros), via de administração (oral, intravenosa e tópica), tipo de população (crianças, adultos e geriátricos ), utente final (hospitais, Clínicas, Centros de Diagnóstico, Ambientes de Assistência Domiciliária e Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online e Outros) – Tendências e previsões do sector para 2031.

Análise e insights do mercado da doença celíaca na América do Norte e na Europa

A dinâmica do mercado na América do Norte e na Europa para a doença celíaca é influenciada por fatores como a crescente prevalência da doença, os avanços nas tecnologias de diagnóstico e um mercado em expansão para os produtos sem glúten. Os prestadores de cuidados de saúde nestas regiões desempenham um papel crucial na sensibilização, na realização de exames e na implementação de estratégias de tratamento. Além disso, o crescente interesse pelas dietas isentas de glúten como opção de estilo de vida entre a população em geral contribui para a expansão do mercado.

Mercado da Doença Celíaca da América do Norte e EuropaMercado da Doença Celíaca da América do Norte e Europa

No geral, o mercado da doença celíaca da América do Norte e da Europa reflete uma interação dinâmica de iniciativas de sensibilização, diagnóstico e investigação para melhorar a vida dos indivíduos afetados por esta condição autoimune. No entanto, o mercado enfrenta desafios como a complexidade da doença e os efeitos secundários associados aos medicamentos utilizados no tratamento da doença celíaca.

Espera-se que o mercado da doença celíaca da América do Norte ganhe crescimento de mercado no período de previsão de 2024 a 2031. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 9,8% no período de previsão de 2024 a 2031 e deverá atingir os 193.364,33 milhares de USD até 2031, contra 94.325,34 milhares de USD em 2023.

Espera-se que o mercado europeu da doença celíaca ganhe crescimento de mercado no período de previsão de 2024 a 2031. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 8,8% no período de previsão de 2024 a 2031 e deverá atingir os 150.949,09 milhares de USD até 2031, contra 78.786,35 milhares de USD em 2023.

Métrica de reporte

Detalhes

Período de previsão

2024 a 2031

Ano base

2023

Anos históricos

2022 (personalizável para 2020-2021)

Unidades Quantitativas

Receita em milhares de dólares, volumes em unidades

Segmentos cobertos

Tipo de tratamento (corticosteróides, imunossupressores e outros), tipo de doença (doença celíaca clássica, doença celíaca não clássica, doença celíaca refractária, doença celíaca potencial e dermatite herpetiforme), tipo de medicamento (genéricos e de marca), tipo de prescrição ( prescrição e mais). de diagnóstico, ambientes de cuidados domiciliários e Outros), Canal de Distribuição (Farmácia Hospitalar, Farmácia de Retalho, Farmácia Online e Outros)

Países abrangidos

EUA, Canadá, México, Alemanha, França, Itália, Espanha, Reino Unido, Suíça, Holanda, Rússia, Turquia, Polónia, Suécia, Bélgica, Dinamarca, Finlândia, Noruega e Resto da Europa

Participantes do mercado abrangidos

Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals (subsidiária da Bausch Health Companies Inc.), Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc., Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics e Equillium Bio. entre outros

Definição de mercado

A doença celíaca é uma doença autoimune crónica caracterizada por uma resposta imunitária anormal à ingestão de glúten – uma proteína presente no trigo, cevada e centeio. Quando os indivíduos com doença celíaca consomem glúten, o seu sistema imunitário ataca erradamente o revestimento do intestino delgado, causando inflamação e danos nas vilosidades, projeções semelhantes a dedos responsáveis ​​pela absorção de nutrientes. Esta reação imunitária resulta numa série de sintomas gastrointestinais e sistémicos, incluindo dor abdominal, diarreia, perda de peso, fadiga e deficiências nutricionais.

O diagnóstico da doença celíaca envolve geralmente uma combinação de análises ao sangue para detetar anticorpos específicos e biópsia intestinal confirmatória. O tratamento primário e vitalício para a doença celíaca é uma dieta rigorosa isenta de glúten. Ao eliminar o glúten da dieta, os indivíduos com doença celíaca podem controlar os sintomas, promover a cura intestinal e prevenir complicações. A adesão a um estilo de vida isento de glúten é crucial, uma vez que mesmo pequenas quantidades de glúten podem desencadear respostas imunitárias e agravar a doença. A doença celíaca pode afetar pessoas de todas as idades e, embora seja uma doença que dura toda a vida, com o tratamento adequado, os indivíduos podem levar uma vida saudável e plena.

Dinâmica do mercado da doença celíaca na América do Norte e na Europa

Motoristas

  • Aumento da prevalência da doença celíaca

A doença celíaca é uma doença autoimune caracterizada pela intolerância ao glúten, uma proteína presente no trigo, cevada e centeio. A prevalência da doença celíaca tem vindo a aumentar nos últimos anos e vários fatores contribuem para este aumento.

Na América do Norte e na Europa, onde a dieta ocidentalizada é predominante, a mudança para o aumento do consumo de glúten amplifica ainda mais o crescimento do mercado. Assim, prevê-se que o aumento da prevalência da doença celíaca atue como impulsionador do mercado da doença celíaca na América do Norte e na Europa.

  • Aumento da procura por produtos que contêm glúten

Os produtos que contêm glúten são feitos de ingredientes que contêm glúten naturalmente. Isto inclui produtos à base de trigo, como pão, massas, doces e cereais. Os produtos à base de cevada e centeio também contêm glúten.

Na panificação, o glúten contribui para o crescimento e textura do pão e de outros produtos de pastelaria. Estes ingredientes são utilizados numa variedade de alimentos, desde produtos assados ​​até massas, até certos molhos e alimentos processados.

A procura de produtos que contenham glúten continua a ser forte na América do Norte e na Europa devido às preferências dos consumidores, às tradições culinárias e ao significado cultural de determinados alimentos. Reflete a preferência mais ampla dos consumidores por alimentos tradicionais ricos em glúten na região, o que aumentará ainda mais o risco de doença celíaca. Assim, prevê-se que o aumento da procura de produtos contendo glúten atue como impulsionador do mercado da doença celíaca na América do Norte e na Europa.

Restrição

  • Complexidade da doença celíaca

A doença celíaca é uma doença autoimune complexa caracterizada por uma resposta imunitária anormal ao glúten, uma proteína presente no trigo, cevada, centeio e seus derivados. A complexidade da doença celíaca surge da intrincada interação de fatores genéticos, imunológicos, ambientais e dietéticos.

Estas complicações tornam a doença celíaca um distúrbio autoimune multifacetado e desafiante de compreender, diagnosticar e tratar. Assim, espera-se que a complexidade da doença celíaca atue como uma restrição para o mercado da doença celíaca da América do Norte e da Europa.

Mercado da Doença Celíaca da América do Norte e Europa

Oportunidade

  • Terapias biológicas emergentes para a doença celíaca

As terapêuticas biológicas emergentes para a doença celíaca representam um caminho promissor para o desenvolvimento de tratamentos alternativos para além do atual padrão de cuidados, que é uma dieta rigorosa e isenta de glúten ao longo da vida. Embora estas terapêuticas ainda se encontrem em fase experimental e em ensaios clínicos, têm o potencial de abordar a complexidade associada à doença celíaca, oferecendo novas possibilidades para os indivíduos afetados por esta doença autoimune. 

O desenvolvimento de terapias biológicas para a doença celíaca reflete uma compreensão crescente dos mecanismos imunológicos subjacentes e um compromisso em encontrar soluções inovadoras para melhorar a qualidade de vida dos indivíduos com esta doença autoimune. À medida que a investigação avança, estas terapias podem oferecer novas opções para o tratamento da doença celíaca, para além das limitações de uma dieta rigorosa isenta de glúten. Assim, espera-se que as terapêuticas biológicas emergentes para a doença celíaca funcionem como uma oportunidade para o mercado da doença celíaca da América do Norte e da Europa.

Desafio

  • Adesão do doente à dieta isenta de glúten

Embora a adesão do doente a uma dieta isenta de glúten seja crucial para a gestão da doença celíaca, apresenta desafios para o mercado da doença celíaca. O mercado da doença celíaca enfrenta desafios porque uma dieta rigorosa isenta de glúten é atualmente o único tratamento eficaz. Com intervenções farmacêuticas limitadas ou terapias alternativas disponíveis, o mercado depende fortemente da adesão dos doentes às restrições alimentares. Esta falta de diversidade de tratamento limita os fluxos de receitas para as empresas farmacêuticas que operam no espaço da doença celíaca.

A adesão dos doentes a uma dieta isenta de glúten coloca desafios ao mercado da doença celíaca, particularmente em termos de opções de tratamento limitadas, considerações económicas e o impacto no desenvolvimento farmacêutico. Assim, espera-se que a adesão do doente à dieta isenta de glúten atue como um desafio para o mercado da doença celíaca da América do Norte e da Europa.

Desenvolvimentos recentes

  • Em outubro de 2022, a Takeda Pharmaceutical Company Limited, a Zedira e a Dr. Falk Pharma GmbH anunciaram um acordo de colaboração e uma licença para desenvolver o ZED1227/TAK-227, um medicamento experimental de Fase 2b para a doença celíaca. Esta colaboração ajudará a empresa a desenvolver o tratamento da doença celíaca
  • Em junho de 2020, a Janssen Pharmaceuticals, Inc. anunciou a colaboração com a Universidade de Monash e assinou uma investigação plurianual para avançar na compreensão dos mecanismos imunológicos subjacentes à doença celíaca e informar o desenvolvimento de novos métodos de diagnóstico e tratamento. A colaboração reúne investigadores líderes e parceiros da indústria para enfrentar este importante problema de saúde e desenvolver imunoterapêuticos inovadores para prevenir e tratar a doença celíaca.

Âmbito do mercado da doença celíaca na América do Norte e na Europa

O mercado da doença celíaca da América do Norte e da Europa está categorizado em nove segmentos notáveis ​​com base no tipo de tratamento, diagnóstico, tipo de doença, tipo de medicamento, tipo de prescrição, forma farmacêutica, via de administração, tipo de população , utilizador final e canal de distribuição. analisa nichos de crescimento e estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.

Tipo de tratamento

  • Corticosteróides
  • Imunossupressores
  • Outros

Com base no tipo de tratamento, o mercado está segmentado em corticosteróides, imunossupressores, entre outros .

Tipo de doença

  • Doença Celíaca Refratária
  • Dermatite Herpetiforme
  • Potencial doença celíaca
  • Doença Celíaca Clássica
  • Doença Celíaca Não Clássica

Com base no tipo de doença, o mercado está segmentado em doença celíaca refratária, dermatite herpetiforme, doença celíaca potencial, doença celíaca clássica e doença celíaca não clássica.

Tipo de droga

  • Genéricos
  • Com marca

Com base no tipo de medicamento, o mercado está segmentado em genéricos e de marca.

Tipo de prescrição

  • Prescrição
  • Em cima do balcão

Com base no tipo de prescrição, o mercado está segmentado em prescrição e venda livre.

Forma farmacêutica

  • Comprimido
  • Cápsulas
  • Injeções
  • Outro

Com base na forma farmacêutica, o mercado está segmentado em comprimidos, cápsulas, injeções, entre outros.

Rota de Administração

  • Oral
  • Intravenoso
  • Tópico

Com base na via de administração, o mercado está segmentado em oral, intravenoso e tópico.

Tipo de população

  • Adultos
  • Crianças
  • Geriátrico

Com base no tipo populacional, o mercado está segmentado em adultos, crianças e geriátricos.

Utilizador final

  • Hospitais
  • Clínicas
  • Configurações de atendimento domiciliário
  • Outros

Com base no utilizador final, o mercado está segmentado em hospitais, clínicas, ambientes de cuidados domiciliários, entre outros.

Canal de distribuição

  • Farmácia Hospitalar
  • Farmácia de Retalho
  • Farmácia on-line
  • Outros

Com base no canal de distribuição, o mercado está segmentado em farmácia hospitalar, farmácia de retalho, farmácia online, entre outros.

Mercado da Doença Celíaca da América do Norte e Europa

América do Norte e Europa Análise/Insights Regionais do Mercado da Doença Celíaca

O mercado é analisado e são fornecidos insights e tendências do tamanho do mercado por país, tipo de tratamento, diagnóstico, tipo de doença, tipo de medicamento, tipo de prescrição, forma farmacêutica, via de administração, tipo de população, utilizador final e canal de distribuição conforme referido acima.

Os países abrangidos neste relatório de mercado EUA, Canadá, México, Alemanha, França, Itália, Espanha, Reino Unido, Suíça, Holanda, Rússia, Turquia, Polónia, Suécia, Bélgica, Dinamarca, Finlândia, Noruega e Resto da Europa.

Espera-se que a região dos EUA domine o mercado devido à forte presença de players de mercado na região. Espera-se que a região da Alemanha domine o mercado devido à elevada prevalência da doença celíaca e às infraestruturas de saúde avançadas.

A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações na regulamentação do mercado interno que impactam as tendências atuais e futuras do mercado. Dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à concorrência grande ou escassa de marcas locais e nacionais, e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país .

Cenário competitivo e análise da quota de mercado da doença celíaca na América do Norte e na Europa

O panorama competitivo do mercado da doença celíaca da América do Norte e da Europa fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em I&D, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, aprovações de produtos, largura e fôlego do produto, domínio de aplicação, tipo de produto linha de vida curva. Os dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado da doença celíaca da América do Norte e da Europa.

Alguns dos principais players que operam no mercado da doença celíaca da América do Norte e da Europa são a Takeda Pharmaceutical Company Limited, a Salix Pharmaceuticals (subsidiária da Bausch Health Companies Inc.), a Tillotts Pharma AG, a GSK plc., a ImmunogenX, Inc., a Janssen Pharmaceuticals , Inc. (subsidiária da Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Terapêutica e Equilíbrio Bio. entre outros.


SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT TYPE LIFELINE CURVE FOR THE NORTH AMERICA CELIAC DISEASE MARKET

2.8 TREATMENT TYPE LIFELINE CURVE THE EUROPE CELIAC DISEASE MARKET

2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.1 DBMR MARKET POSITION GRID

2.11 MARKET END USER COVERAGE GRID

2.12 VENDOR SHARE ANALYSIS

2.13 SECONDARY SOURCES

2.14 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTAL ANALYSIS

4.2 PORTERS 5 FORCES

4.3 EPIDEMIOLOGY

5 PIPELINE ANALYSIS

6 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, REGULATORY FRAMEWORK

6.1 REGULATIONS IN NORTH AMERICA

6.1.1 U.S.

6.1.2 CANADA

6.2 REGULATIONS IN EUROPE

6.2.1 EUROPEAN UNION (EU)

6.2.2 U.K.

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF CELIAC DISEASE

7.1.2 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS

7.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR CELIAC DISEASE TREATMENTS

7.1.4 GROWING AWARENESS ABOUT CELIAC DISEASE

7.2 RESTRAINTS

7.2.1 COMPLEXITY OF CELIAC DISEASE

7.2.2 LIMITED TREATMENT OPTIONS FOR CELIAC DISEASE

7.3 OPPORTUNITIES

7.3.1 EMERGING BIOLOGICAL THERAPIES FOR CELIAC DISEASE

7.3.2 RISING ADVANCEMENTS IN DIAGNOSTIC APPROACHES OF CELIAC DISEASE

7.3.3 STRATEGIC COLLABORATION FOR COMMERCIALIZATION OF NOVEL THERAPIES FOR CELIAC DISEASE

7.4 CHALLENGES

7.4.1 PATIENT ADHERENCE TO GLUTEN-FREE DIET

7.4.2 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS USED FOR CELIAC DISEASE TREATMENT

8 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 CORTICOSTERIODS

8.2.1 PREDNISONE

8.2.2 .BUDESONIDE

8.2.3 BETAMETHASONE

8.2.4 CLOBETASONE BUTYRATE

8.2.5 OTHERS

8.3 IMMUNOSUPPRESSANTS

8.3.1 AZATHIOPRINE

8.3.2 INFLIXIMAB

8.3.3 CYCLOSPORINE

8.3.4 CLADRIBINE

8.3.5 OTHERS

8.4 OTHERS

9 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 REFRACTORY CELIAC DISEASE

9.2.1 TYPE I

9.2.2 TYPE II

9.3 DERMATITIS HERPETIFORMIS

9.4 POTENTIAL CELIAC DISEASE

9.5 CLASSICAL CELIAC DISEASE

9.6 NON-CLASSICAL CELIAC DISEASE

10 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE

10.1 OVERVIEW

10.2 GENERICS

10.3 BRANDED

11 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE

11.1 OVERVIEW

11.2 PRESCRIPTION

11.3 OVER THE COUNTER

12 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM

12.1 OVERVIEW

12.2 TABLET

12.3 CAPSULES

12.4 INJECTIONS

12.5 OTHER

13 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION

13.1 OVERVIEW

13.2 ORAL

13.2.1 TABLET

13.2.2 CAPSULES

13.2.3 OTHERS

13.3 INTRAVENOUS

13.4 TOPICAL

14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE

14.1 OVERVIEW

14.2 ADULTS

14.2.1 FEMALE

14.2.2 MALE

14.3 CHILDREN

14.4 GERIATRIC

14.4.1 FEMALE

14.4.2 MALE

15 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 CLINICS

15.4 HOME CARE SETTINGS

15.5 OTHERS

16 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 HOSPITAL PHARMACY

16.3 RETAIL PHARMACY

16.4 ONLINE PHARMACY

16.5 OTHERS

17 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET, BY GEOGRAPHY

17.1 NORTH AMERICA

17.1.1 U.S.

17.1.2 CANADA

17.1.3 MEXICO

17.2 EUROPE

17.2.1 GERMANY

17.2.2 FRANCE

17.2.3 ITALY

17.2.4 SPAIN

17.2.5 U.K.

17.2.6 SWITZERLAND

17.2.7 NETHERLANDS

17.2.8 RUSSIA

17.2.9 TURKEY

17.2.10 POLAND

17.2.11 SWEDEN

17.2.12 BELGIUM

17.2.13 DENMARK

17.2.14 FINLAND

17.2.15 NORWAY

17.2.16 REST OF EUROPE

18 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

19 EUROPE CELIAC DISEASE MARKET: COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: EUROPE

20 SWOT ANALYSIS

21 COMPANY PROFILES

21.1 GSK PLC.

21.1.1 COMPANY SNAPSHOT

21.1.2 REVENUE ANALYSIS

21.1.3 PRODUCT PORTFOLIO

21.1.4 RECENT DEVELOPMENT

21.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 PRODUCT PORTFOLIO

21.2.4 RECENT DEVELOPMENT

21.3 PFIZER INC.

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 PRODUCT PORTFOLIO

21.3.4 RECENT DEVELOPMENT

21.4 TEVA PHARMACEUTICALS USA, INC.

21.4.1 COMPANY SNAPSHOT

21.4.2 REVENUE ANALYSIS

21.4.3 PRODUCT PORTFOLIO

21.4.4 RECENT DEVELOPMENT

21.5 NOVARTIS AG

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 PRODUCT PORTFOLIO

21.5.4 RECENT DEVELOPMENT

21.6 ADVACARE PHARMA

21.6.1 COMPANY SNAPSHOT

21.6.2 PRODUCT PORTFOLIO

21.6.3 RECENT DEVELOPMENT

21.7 AMGEN INC.

21.7.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANALYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENT

21.8 ANOKION

21.8.1 COMPANY SNAPSHOT

21.8.2 PRODUCT PORTFOLIO

21.8.3 RECENT DEVELOPMENT

21.9 EQUILLIUM BIO.

21.9.1 COMPANY SNAPSHOT

21.9.2 PRODUCT PORTFOLIO

21.9.3 RECENT DEVELOPMENT

21.1 IMMUNIC THERAPEUTICS

21.10.1 COMPANY SNAPSHOT

21.10.2 PRODUCT PORTFOLIO

21.10.3 RECENT DEVELOPMENT

21.11 IMMUNOGENX, INC.

21.11.1 COMPANY SNAPSHOT

21.11.2 PRODUCT PORTFOLIO

21.11.3 RECENT DEVELOPMENT

21.12 SALIX PHARMACEUTICALS (SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC.)

21.12.1 COMPANY SNAPSHOT

21.12.2 REVENUE ANALYSIS OF PARENT COMPANY

21.12.3 PRODUCT PORTFOLIO

21.12.4 RECENT DEVELOPMENT

21.13 TAKEDA PHARMACEUTICAL COMPANY LIMITED

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENT

21.14 TILLOTTS PHARMA AG

21.14.1 COMPANY SNAPSHOT

21.14.2 PRODUCT PORTFOLIO

21.14.3 RECENT DEVELOPMENT

21.15 TOPAS THERAPEUTICS

21.15.1 COMPANY SNAPSHOT

21.15.2 PRODUCT PORTFOLIO

21.15.3 RECENT DEVELOPMENT

22 QUESTIONNAIRE

23 RELATED REPORTS

Lista de Tabela

TABLE 1 PIPELINE ANALYSIS FOR NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET

TABLE 2 NORTH AMERICA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 3 EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 4 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 5 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 6 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 7 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 10 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 11 EUROPE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 12 NORTH AMERICA CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND)

TABLE 13 EUROPE CELIAC DISEASE MARKET, BY DISEASE TYPE, 2022-2031 (USD THOUSAND)

TABLE 14 NORTH AMERICA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 15 EUROPE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 16 NORTH AMERICA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 17 EUROPE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 18 NORTH AMERICA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 19 EUROPE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 20 NORTH AMERICA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 21 EUROPE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 22 NORTH AMERICA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 23 EUROPE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 24 NORTH AMERICA CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 25 EUROPE CORTICOSTERIODS IN CELIAC DISEASE MARKET, BY PRODUCT, 2022-2031 (USD THOUSAND)

TABLE 26 NORTH AMERICA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 27 EUROPE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 28 NORTH AMERICA ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 29 EUROPE ADULTS IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 30 NORTH AMERICA GERIATRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 31 EUROPE GERAITRIC IN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 32 NORTH AMERICA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 33 EUROPE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 34 NORTH AMERICA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 35 EUROPE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 36 NORTH AMERICA CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 37 U.S. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 38 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 39 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 40 U.S. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 41 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 42 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 43 U.S. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 44 U.S. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 45 U.S. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 46 U.S. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 47 U.S. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 48 U.S. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 49 U.S. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 50 U.S. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 51 U.S. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 52 U.S. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 53 U.S. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 54 U.S. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 55 U.S. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 56 CANADA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 57 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 58 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 59 CANADA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 60 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 61 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 62 CANADA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 63 CANADA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 64 CANADA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 65 CANADA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 66 CANADA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 67 CANADA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 68 CANADA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 69 CANADA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 70 CANADA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 71 CANADA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 72 CANADA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 73 CANADA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 74 CANADA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 75 MEXICO CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 76 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 77 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 78 MEXICO CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 79 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 80 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 81 MEXICO IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 82 MEXICO CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 83 MEXICO REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 84 MEXICO CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 85 MEXICO CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 86 MEXICO CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 87 MEXICO CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 88 MEXICO ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 89 MEXICO CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 90 MEXICO ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 91 MEXICO GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 92 MEXICO CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 93 MEXICO CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 94 EUROPE CELIAC DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND)

TABLE 95 GERMANY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 96 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 97 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 98 GERMANY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 99 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 100 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 101 GERMANY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 102 GERMANY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 103 GERMANY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 104 GERMANY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 105 GERMANY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 106 GERMANY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 107 GERMANY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 108 GERMANY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 109 GERMANY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 110 GERMANY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 111 GERMANY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 112 GERMANY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 113 GERMANY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 114 FRANCE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 115 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 116 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 117 FRANCE CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 118 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 119 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 120 FRANCE IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 121 FRANCE CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 122 FRANCE REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 123 FRANCE CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 124 FRANCE CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 125 FRANCE CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 126 FRANCE CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 127 FRANCE ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 128 FRANCE CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 129 FRANCE ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 130 FRANCE GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 131 FRANCE CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 132 FRANCE CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 133 ITALY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 134 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 135 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 136 ITALY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 137 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 138 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 139 ITALY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 140 ITALY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 141 ITALY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 142 ITALY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 143 ITALY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 144 ITALY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 145 ITALY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 146 ITALY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 147 ITALY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 148 ITALY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 149 ITALY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 150 ITALY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 151 ITALY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 152 SPAIN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 153 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 154 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 155 SPAIN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 156 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 157 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 158 SPAIN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 159 SPAIN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 160 SPAIN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 161 SPAIN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 162 SPAIN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 163 SPAIN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 164 SPAIN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 165 SPAIN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 166 SPAIN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 167 SPAIN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 168 SPAIN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 169 SPAIN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 170 SPAIN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 171 U.K. CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 172 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 173 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 174 U.K. CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 175 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 176 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 177 U.K. IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 178 U.K. CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 179 U.K. REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 180 U.K. CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 181 U.K. CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 182 U.K. CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 183 U.K. CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 184 U.K. ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 185 U.K. CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 186 U.K. ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 187 U.K. GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 188 U.K. CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 189 U.K. CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 190 SWITZERLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 191 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 192 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 193 SWITZERLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 194 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 195 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 196 SWITZERLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 197 SWITZERLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 198 SWITZERLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 199 SWITZERLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 200 SWITZERLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 201 SWITZERLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 202 SWITZERLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 203 SWITZERLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 204 SWITZERLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 205 SWITZERLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 206 SWITZERLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 207 SWITZERLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 208 SWITZERLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 209 NETHERLANDS CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 210 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 211 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 212 NETHERLANDS CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 213 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 214 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 215 NETHERLANDS IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 216 NETHERLANDS CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 217 NETHERLANDS REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 218 NETHERLANDS CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 219 NETHERLANDS CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 220 NETHERLANDS CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 221 NETHERLANDS CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 222 NETHERLANDS ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 223 NETHERLANDS CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 224 NETHERLANDS ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 225 NETHERLANDS GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 226 NETHERLANDS CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 227 NETHERLANDS CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 228 RUSSIA CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 229 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 230 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 231 RUSSIA CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 232 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 233 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 234 RUSSIA IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 235 RUSSIA CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 236 RUSSIA REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 237 RUSSIA CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 238 RUSSIA CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 239 RUSSIA CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 240 RUSSIA CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 241 RUSSIA ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 242 RUSSIA CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 243 RUSSIA ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 244 RUSSIA GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 245 RUSSIA CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 246 RUSSIA CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 247 TURKEY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 248 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 249 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 250 TURKEY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 251 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 252 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 253 TURKEY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 254 TURKEY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 255 TURKEY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 256 TURKEY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 257 TURKEY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 258 TURKEY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 259 TURKEY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 260 TURKEY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 261 TURKEY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 262 TURKEY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 263 TURKEY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 264 TURKEY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 265 TURKEY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 266 POLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 267 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 268 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 269 POLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 270 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 271 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 272 POLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 273 POLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 274 POLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 275 POLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 276 POLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 277 POLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 278 POLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 279 POLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 280 POLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 281 POLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 282 POLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 283 POLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 284 POLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 285 SWEDEN CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 286 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 287 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 288 SWEDEN CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 289 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 290 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 291 SWEDEN IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 292 SWEDEN CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 293 SWEDEN REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 294 SWEDEN CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 295 SWEDEN CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 296 SWEDEN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 297 SWEDEN CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 298 SWEDEN ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 299 SWEDEN CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 300 SWEDEN ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 301 SWEDEN GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 302 SWEDEN CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 303 SWEDEN CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 304 BELGIUM CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 305 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 306 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 307 BELGIUM CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 308 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 309 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 310 BELGIUM IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 311 BELGIUM CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 312 BELGIUM REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 313 BELGIUM CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 314 BELGIUM CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 315 BELGIUM CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 316 BELGIUM CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 317 BELGIUM ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 318 BELGIUM CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 319 BELGIUM ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 320 BELGIUM GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 321 BELGIUM CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 322 BELGIUM CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 323 DENMARK CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 324 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 325 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 326 DENMARK CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 327 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 328 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 329 DENMARK IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 330 DENMARK CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 331 DENMARK REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 332 DENMARK CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 333 DENMARK CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 334 DENMARK CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 335 DENMARK CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 336 DENMARK ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 337 DENMARK CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 338 DENMARK ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 339 DENMARK GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 340 DENMARK CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 341 DENMARK CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 342 FINLAND CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 343 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 344 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 345 FINLAND CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 346 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 347 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 348 FINLAND IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 349 FINLAND CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 350 FINLAND REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 351 FINLAND CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 352 FINLAND CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 353 FINLAND CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 354 FINLAND CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 355 FINLAND ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 356 FINLAND CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 357 FINLAND ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 358 FINLAND GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 359 FINLAND CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 360 FINLAND CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 361 NORWAY CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

TABLE 362 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 363 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (UNITS)

TABLE 364 NORWAY CORTICOSTEROIDS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 365 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 366 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE , 2022-2031 (UNITS)

TABLE 367 NORWAY IMMUNOSUPPRESSANTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (ASP PER UNIT)

TABLE 368 NORWAY CELIAC DISEASE MARKET, BY DISEASES TYPE, 2022-2031 (USD THOUSAND)

TABLE 369 NORWAY REFRACTORY CELIAC DISEASE IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 370 NORWAY CELIAC DISEASE MARKET, BY DRUG TYPE, 2022-2031 (USD THOUSAND)

TABLE 371 NORWAY CELIAC DISEASE MARKET, BY PRESCRIPTION TYPE, 2022-2031 (USD THOUSAND)

TABLE 372 NORWAY CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 373 NORWAY CELIAC DISEASE MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)

TABLE 374 NORWAY ORAL IN CELIAC DISEASE MARKET, BY DOSAGE FORM, 2022-2031 (USD THOUSAND)

TABLE 375 NORWAY CELIAC DISEASE MARKET, BY POPULATION TYPE, 2022-2031 (USD THOUSAND)

TABLE 376 NORWAY ADULTS IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 377 NORWAY GERIATRIC IN CELIAC DISEASE MARKET, BY TYPE, 2022-2031 (USD THOUSAND)

TABLE 378 NORWAY CELIAC DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND)

TABLE 379 NORWAY CELIAC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)

TABLE 380 REST OF EUROPE CELIAC DISEASE MARKET, BY TREATMENT TYPE, 2022-2031 (USD THOUSAND)

Lista de Figura

FIGURE 1 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 EUROPE CELIAC DISEASE MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 6 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 7 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE CELIAC DISEASE MARKET: DBMR MARKET POSITION GRID

FIGURE 10 NORTH AMERICA CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID

FIGURE 11 EUROPE CELIAC DISEASE MARKET: MARKET END USER COVERAGE GRID

FIGURE 12 NORTH AMERICA CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS

FIGURE 13 EUROPE CELIAC DISEASE MARKET: VENDOR SHARE ANALYSIS

FIGURE 14 NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET: SEGMENTATION

FIGURE 15 THE INCREASING PREVALENCE OF CELIAC DISEASE IS DRIVING THE GROWTH OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 16 RISING CONSUMPTION OF GLUTEN-CONTAINING PRODUCTS IS DRIVING THE GROWTH OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 17 CORTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031

FIGURE 18 CARTICOSTEROIDS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CELIAC DISEASE MARKET IN THE FORECAST PERIOD OF 2024 AND 2031

FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA AND EUROPE CELIAC DISEASE MARKET

FIGURE 20 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023

FIGURE 21 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)

FIGURE 22 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031)

FIGURE 23 NORTH AMERICA CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 24 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2023

FIGURE 25 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, 2024-2031 (USD THOUSAND)

FIGURE 26 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, CAGR (2024-2031)

FIGURE 27 EUROPE CELIAC DISEASE MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023

FIGURE 29 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND)

FIGURE 30 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031)

FIGURE 31 NORTH AMERICA CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 32 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2023

FIGURE 33 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, 2024-2031 (USD THOUSAND)

FIGURE 34 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, CAGR (2024-2031)

FIGURE 35 EUROPE CELIAC DISEASE MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 36 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2023

FIGURE 37 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 38 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 39 NORTH AMERICA CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 40 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2023

FIGURE 41 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, 2024-2031 (USD THOUSAND)

FIGURE 42 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, CAGR (2024-2031)

FIGURE 43 EUROPE CELIAC DISEASE MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 44 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023

FIGURE 45 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 46 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031)

FIGURE 47 NORTH AMERICA CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE

FIGURE 48 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2023

FIGURE 49 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 50 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, CAGR (2024-2031)

FIGURE 51 EUROPE CELIAC DISEASE MARKET: BY PRESCRIPTION TYPE, LIFELINE CURVE

FIGURE 52 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023

FIGURE 53 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)

FIGURE 54 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031)

FIGURE 55 NORTH AMERICA CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 56 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2023

FIGURE 57 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, 2024-2031 (USD THOUSAND)

FIGURE 58 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, CAGR (2024-2031)

FIGURE 59 EUROPE CELIAC DISEASE MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 60 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 61 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 62 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 63 NORTH AMERICA CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 64 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 65 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)

FIGURE 66 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 67 EUROPE CELIAC DISEASE MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 68 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023

FIGURE 69 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 70 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031)

FIGURE 71 NORTH AMERICA CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 72 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2023

FIGURE 73 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, 2024-2031 (USD THOUSAND)

FIGURE 74 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, CAGR (2024-2031)

FIGURE 75 EUROPE CELIAC DISEASE MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 76 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2023

FIGURE 77 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 78 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031)

FIGURE 79 NORTH AMERICA CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE

FIGURE 80 EUROPE CELIAC DISEASE MARKET: BY END USER, 2023

FIGURE 81 EUROPE CELIAC DISEASE MARKET: BY END USER, 2024-2031 (USD THOUSAND)

FIGURE 82 EUROPE CELIAC DISEASE MARKET: BY END USER, CAGR (2024-2031)

FIGURE 83 EUROPE CELIAC DISEASE MARKET: BY END USER, LIFELINE CURVE

FIGURE 84 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 85 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 86 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 87 NORTH AMERICA CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 88 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 89 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)

FIGURE 90 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 91 EUROPE CELIAC DISEASE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 92 NORTH AMERICA CELIAC DISEASE MARKET: SNAPSHOT (2023)

FIGURE 93 EUROPE CELIAC DISEASE MARKET: SNAPSHOT (2023)

FIGURE 94 NORTH AMERICA CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%)

FIGURE 95 EUROPE CELIAC DISEASE MARKET: COMPANY SHARE 2023 (%)

View Detailed Information Right Arrow

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

The North America and Europe Celiac Disease Market size will be worth USD 150,949.09 thousand during the forecast period by 2031.
The North America and Europe Celiac Disease Market growth rate is 8.8% during the forecast period.
Increasing Prevalence Of Celiac Disease & Rising Demand For Gluten Containing Products are the growth drivers of the North America and Europe Celiac Disease Market.
The treatment type, diagnosis, disease type, drug type, prescription type, dosage form, route of administration, population type, end user and distribution channel are the factors on which the North America and Europe Celiac Disease Market research is based.
Major companies in the North America and Europe Celiac Disease Market are Tillotts Pharma AG, GSK plc., ImmunogenX, Inc., Janssen Pharmaceuticals, Inc. (subsidiary of Johnson & Johnson Services, Inc.), Teva Pharmaceuticals USA, Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., AstraZeneca, Novartis AG, AdvaCare Pharma, ANOKION, Topas Therapeutics, Immunic Therapeutics and Equillium Bio.